Following those findings, Parker et al. [6] proposed a 50-gene Prediction Analysis of Microarray (PAM50), which aimed to predict the chemotherapy benefit and breast cancer prognosis and allowed the intrinsic subtype diagnosis for five molecular subtypes: basal-like, HER2-enriched, luminal A, luminal B, and normal-like. This evidence concerns the gene ERBB2 and breast cancer.